# Supplementary Material

# Anticancer Potential of Some Imidazole and Fused Imidazole Derivatives: Exploring mechanism via Epidermal Growth Factor Receptor (EGFR) Inhibition

Sourav Kalra,<sup>a</sup> Gaurav Joshi,<sup>b</sup> Manvendra Kumar,<sup>b</sup> Sahil Arora,<sup>b</sup> Harsimrat Kaur,<sup>c</sup> Sandeep Singh,<sup>a</sup>\* Anjana Munshi,<sup>a</sup>\* and Raj Kumar<sup>b</sup>\*\*

<sup>a</sup>Department of Human Genetics and Molecular Medicine, School of Health Sciences; <sup>b</sup>Department of Pharmaceutical Sciences and Natural Products, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151001


<sup>c</sup>Desh Bhagat Dental College and Hospital, Mandi Gobindgarh, India


\*\*E-mail: <u>raj.khunger@gmail.com;</u> <u>rajcps@cup.ac.in</u>


Co-corresponding authors\*E-mail: anjanadurani@yahoo.co.in; sandeepsingh82@gmail.com

# Spectra for representative compounds

Data <sup>1</sup>H , <sup>13</sup>C NMR, and HRMS










#### Single Mass Analysis


Tolerance = 3.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 5



Page 1










### Page 1

#### Single Mass Analysis



Line#:1 R.Time:4.000(Scan#:501) MassPeaks:336 RawMode:Averaged 4.000-4.005(501-502) BasePeak:166(3373) BG Mode:Calc. from Peak Group 1 - Event 1 intensity







### Page 1


#### Single Mass Analysis


Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 5



Line#:1 R.Time:3.420(Scan#:385) MassPeaks:365 RawMode:Averaged 3.415-3.425(384-386) BasePeak:202(290256) BG Mode:Calc. from Peak Group 1 - Event 1 intensity









#### Page 1

#### Single Mass Analysis

Tolerance = 6.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 5


Monoisotopic Mass, Odd and Even Electron Ions 46 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 9-20 H: 11-30 N: 0-5 O: 0-3 F: 0-1 Sample Name : A-4 IITRPR XEVO G2-XS QTOF : HRMS-1 Test Name 160120-A-4 16 (0.165) 1: TOF MS ES+ 1.57e+005 337.1081 100-OH NC 340.2602 318,2990 1d % 301.9575 302.3053 340.7607 359.2387 354.2849 319.3029 389.1453 393.2125 413.2675 425.2156431.0900 303.3100 363.2453 375.2130 448.2209 ullu m/z 310 320 330 350 360 370 390 300 340 380 420 430 400 410 440 450 Minimum: -1.5 Maximum: 5.0 6.0 50.0 Mass Calc. Mass mDa PPM DBE i-FIT Norm Conf(%) Formula 337.1081 337.1101 -2.0 -5.9 13.5 1087.3 n/a n/a C18 H14 N4 O2 F







#### Page 1


#### Single Mass Analysis







MassPeaks:557 RawMode:Averaged 6.265-6.275(954-956) BasePeak:306(2138462) BG Mode:Calc. from Peak Group 1 - Event 1 intensity












#### Page 1


#### Single Mass Analysis






Line#:1 R.Time:2.155(Scan#:132) MassPeaks:430 intensity







#### Page 1


#### Single Mass Analysis






Spectrum






#### Page 1


#### Single Mass Analysis







Spectrum


Line#:1 R.Time:7.425(Scan#:1186) MassPeaks:583 RawMode:Averaged 7.420-7.430(1185-1187) BasePeak:380(6661844) BG Mode:Calc. from Peak Group 1 - Event 1 intensity











Line#:1 R.Time:4.880(Scan#:677) MassPeaks:519 RawMode:Averaged 4.875-4.885(676-678) BasePeak:332(535382) BG Mode:Calc. from Peak Group 1 - Event 1 intensity













Line#:2 R.Time:6.590(Scan#:1019) MassPeaks:567 RawMode:Averaged 6.585-6.595(1018-1020) BasePeak:109(2294380) BG Mode:Calc. from Peak Group 1 - Event 1 intensity







# **Elemental Composition Report**


# Page 1


#### Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 5














Line#:1 R.Time:5.910(Scan#:883) MassPeaks:561 RawMode:Averaged 5.905-5.915(882-884) BasePeak:109(2769141) BG Mode:Calc. from Peak Group 1 - Event 1 intensity
























SA-11



Line#:2 R.Time:5.600(Scan#:821) MassPeaks:564 RawMode:Averaged 5.595-5.605(820-822) BasePeak:109(3565792) BG Mode:Calc. from Peak Group 1 - Event 1 intensity








SA-12H


# **Elemental Composition Report**


# Page 1


#### Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 5













SA-13





# Series 2





# **Elemental Composition Report**


# Page 1


#### Single Mass Analysis


Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 5


Monoisotopic Mass, Even Electron Ions 65 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 9-22 H: 8-25 N: 0-5 O: 0-3 F: 0-1 Sample Name : Int-2 IITRPR XEVO G2-XS QTOF Test Name : HRMS-1 160120-Int-2 12 (0.131) 1: TOF MS ES+ 1.59e+008 203.0736 HN 100-CN Ν NH<sub>2</sub> 153.1396 230.0837 %-9 154.1391 266.2204 338.2414 395.1517 I 249.0744 297.0909 314.1197 197.1273 432.0962 485.1382 L. I. # m/z 180 200 220 280 300 320 340 360 380 420 440 460 160 240 260 400 480 500 Minimum: -1.5 Maximum: 5.0 5.0 50.0 Mass Calc. Mass mDa PPM DBE i-FIT Norm Conf(%) Formula 230.0837 230.0842 -0.5 -2.2 9.5 2053.6 n/a n/a C11 H9 N5 F


Line#:2 R.Time:5.775(Scan#:856) MassPeaks:687 RawMode:Averaged 5.770-5.780(855-857) BasePeak:273(1487875) BG Mode:Calc. from Peak Group 1 - Event 1 intensity






































## **Elemental Composition Report**


### Page 1

#### Single Mass Analysis


Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 5


Monoisotopic Mass, Even Electron Ions 37 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 9-22 H: 6-25 N: 0-5 O: 0-3 F: 0-1 Sample Name : SRA-14 IITRPR XEVO G2-XS QTOF Test Name : HRMS-1 160120-SRA-14 16 (0.165) 1: TOF MS ES+ 4.43e+007 376.1566 H<sub>2</sub>NOC 100-**2d** % 377.1576 773.2848 331,1331 398,1366 751.3035 774.2881 399.1396 492.1249 835.2571 217.0128 285.5680 582.7035 646.2105 m/z 200 300 750 250 350 400 450 500 550 600 650 700 800 150 850 Minimum: -1.5 Maximum: 5.0 5.0 50.0 Mass Calc. Mass mDa PPM DBE i-FIT Norm Conf(%) Formula n/a 376.1566 376.1574 -0.8 -2.1 14.5 1626.0 n/a C21 H19 N5 O F


Line#2 R.Time:7.485(Scan#:1198) MassPeaks:487 RawMode:Averaged 7.480-7.490(1197-1199) BasePeak:94(1695199) BG Mode:Calc. from Peak Group 1 - Event 1 intensity




Line#1 R.Time:6.935(Scan#:1088) MassPeaks:431 RawMode:Averaged 6.930-6.940(1087-1089) BasePeak:156(346019) BG Mode:Calc. from Peak Group 1 - Event 1 intensity










## Molecular docking of 3c in HER-2 and other proteins

We performed molecular docking of most potent compound 3c into the HER-2 kinase and other related proteins such as CDK-2, 4, 6, ER $\alpha$  and PR and results were compared with their positive controls (Table S1). The Figure S1 represents the 3D binding pose of the lapatinib (positive control) and the compound 3c in the active site of the HER-2 (PDB: 3RCD). The laptinib occupied more surface are of 521.59 Å<sup>2</sup> of binding cavity of HER-2 protein than compound 3c (471.50 Å<sup>2</sup>). This could be due to the presence of an extra flurophenyl ring in lapatanib structure which increases the surface area of lapatinib by 50 Å<sup>2</sup> and supports the crucial  $\pi$ -  $\pi$  interaction with PHE891 (Figure S1). Moreover, it was observed that lapatinib binding to active site was favoured by the hydrophobic interaction (LEU796, MET 801 and PHE891) and salt bridge interaction (ASP808) whereas compound 3c showed only one hydrophobic interaction (MET801), one polar interaction (GLN799) and one salt bridge interaction with LYS753 and hence lapatinib showed better dock score (-12.39) than our compound 3c (-6.08).



**Figure S1:** Represents the structure of lapatinib (yellow) and compound **3c** (green) in HER-2 protein (PDB: 3RCD) with important flurophenyl ring in lapatinib that increases surface area of lapatinib by 50 Å<sup>2</sup> and supports  $\pi$ -  $\pi$  interaction with PHE891.

Similarly, docking results of compound 3c were not favourable with other proteins as well (CDK-2, 4, 6, ER $\alpha$  and PR). We already mentioned in the manuscript that 3c did not inhibit Cyclin dependant kinases (CDKs) under in vitro condition which could be due to poor binding and docking scores (Table S1). Compound 3c could not even enter binding cavity of some PR. Therefore, EGDR inhibition could seem to be one of the major anticancer mechanisms.

Protein	ID	Positive Control (Dock Score)	Dock Score (Compound 3c)	2D interaction with 3c
CDK2	5L2W	(Jock Score) Dinacicilib (-13.46)	-5.47	
CDK4	2W9Z	Pablocicilib	No co-crystallized ligand	

# Table S1: Docking of compound 3c into other proteins

		(NA)		
CDK6	2EUF	Pablocicilib (-10.46)	-6.82	$ \left( \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$

HER2	3RCD	Lapatinib		
HEK2	SRCD	(-12.39)	-6.03	

ERα	5W9C	Tamoxifen (-12.75)	-2.78	
PR	2W8Y	Mifepristone (NA)	Not entered in cavity	